YU30504A - Postupak za dobijanje supstituisanih pirazola - Google Patents
Postupak za dobijanje supstituisanih pirazolaInfo
- Publication number
- YU30504A YU30504A YU30504A YUP30504A YU30504A YU 30504 A YU30504 A YU 30504A YU 30504 A YU30504 A YU 30504A YU P30504 A YUP30504 A YU P30504A YU 30504 A YU30504 A YU 30504A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- substituted pyrazoles
- making substituted
- pyrazoles
- making
- tautomers
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 150000003217 pyrazoles Chemical class 0.000 title abstract 4
- -1 benzoyl halide Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 1
- 150000007857 hydrazones Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
Abstract
Ovaj pronalazak je usmeren na postupak za dobijanje supstituisanih pirazola (I), tautomera tih supstituisanih pirazola i soli tih supstituisanih pirazola i tautomera, gde su R3A, R3B, R3C, Y1, Y2, Y3, Y4 i Y5 definisani u ovoj prijavi. Ovaj postupak se sastoji od: formiranja smeše postupkom uvođenja hidrazona (II) i opciono supstituisanog benzoilhalida (III) u reaktor, pa zagrevanja te smeše iznad 50В°C (II); (III).[This invention is directed to a process for making substituted pyrazoles, (I) tautomers of the substituted pyrazoles, and salts of the substituted pyrazoles and tautomers, wherein R3A, R3B, R3C, Y1, Y2, Y3, Y4, and Y5 are as defined in the specification. The process comprises: forming a mixture by a process comprising introducing a hydrazone (II) and an optionally-substituted benzoyl halide (III) into a reactor, and heating the mixture to a temparature of greater than 50 В°C (II); and (III).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32498701P | 2001-09-25 | 2001-09-25 | |
| US38126102P | 2002-05-17 | 2002-05-17 | |
| US38369102P | 2002-05-28 | 2002-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU30504A true YU30504A (sh) | 2006-08-17 |
Family
ID=27406371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU30504A YU30504A (sh) | 2001-09-25 | 2002-09-25 | Postupak za dobijanje supstituisanih pirazola |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6897318B2 (sh) |
| EP (1) | EP1429773A1 (sh) |
| JP (1) | JP2005508911A (sh) |
| KR (1) | KR100697482B1 (sh) |
| CN (1) | CN1321644C (sh) |
| AU (1) | AU2002330096B2 (sh) |
| BR (1) | BR0212812A (sh) |
| CA (1) | CA2461095A1 (sh) |
| IL (1) | IL161009A0 (sh) |
| MX (1) | MXPA04002855A (sh) |
| PL (1) | PL369497A1 (sh) |
| WO (1) | WO2003026663A1 (sh) |
| YU (1) | YU30504A (sh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7057049B2 (en) | 2001-09-25 | 2006-06-06 | Pharmacia Corporation | Process for making substituted pyrazoles |
| CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
| WO2005061485A1 (en) * | 2003-12-18 | 2005-07-07 | Pharmacia Corporation | Process for making substituted pyrazoles |
| JP5658284B2 (ja) * | 2010-01-27 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｒｔｈ２アンタゴニストとしてのピラゾール化合物 |
| CN105308032B (zh) | 2013-04-12 | 2017-05-24 | 拜耳作物科学股份公司 | 新的三唑衍生物 |
| MX2015014268A (es) | 2013-04-12 | 2016-06-02 | Bayer Cropscience Ag | Derivados de triazol novedosos. |
| BR112015025331A2 (pt) | 2013-04-12 | 2017-07-18 | Bayer Cropscience Ag | novos derivados de triazolintiona |
| MX2017012709A (es) | 2015-04-02 | 2017-11-23 | Bayer Cropscience Ag | Nuevos derivados de imidazolilmetilo 5-sustituidos. |
| JP2018511608A (ja) | 2015-04-02 | 2018-04-26 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺真菌剤としてのトリアゾール誘導体 |
| CR20190128A (es) | 2016-09-13 | 2019-05-15 | Bayer Ag | Combinaciones de compuesto activo que comprenden un derivado de imidazol sustituido en la posición 5 |
| EP3519408A1 (en) | 2016-09-29 | 2019-08-07 | Bayer CropScience Aktiengesellschaft | 1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection |
| EP3519391A1 (en) | 2016-09-29 | 2019-08-07 | Bayer CropScience Aktiengesellschaft | Novel 5-substituted imidazolylmethyl derivatives |
| WO2018060073A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazole derivatives |
| EP3710432A1 (en) | 2017-11-13 | 2020-09-23 | Bayer Aktiengesellschaft | Tetrazolylpropyl derivatives and their use as fungicides |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1261124B (de) | 1961-09-22 | 1968-02-15 | Hoechst Ag | Verfahren zur Herstellung von Pyrazolen |
| GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
| US3984431A (en) | 1972-03-15 | 1976-10-05 | Claude Gueremy | Derivatives of pyrazole-5-acetic acid |
| FR2509729A1 (fr) | 1981-07-15 | 1983-01-21 | Pharmindustrie | Nouveau procede de preparation de derives du diphenyl-3,4 methyl-5 pyrazole |
| DE3300795A1 (de) | 1983-01-12 | 1984-07-12 | Bayer Ag, 5090 Leverkusen | Substituierte 4-imidazolyl-pyrazole, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel |
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
| JPH04145081A (ja) | 1990-10-06 | 1992-05-19 | Kumiai Chem Ind Co Ltd | ピラゾールカルボン酸誘導体及び除草剤 |
| WO1992019615A2 (en) | 1991-04-24 | 1992-11-12 | E.I. Du Pont De Nemours And Company | Fungicidal pyrazoles, pyrazolines and tetrahydropyridazines |
| GB9204958D0 (en) | 1992-03-06 | 1992-04-22 | Fujisawa Pharmaceutical Co | Thiazole derivatives |
| DE4328228A1 (de) * | 1993-08-23 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von Pyrazol und dessen Derivaten |
| US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| JPH0899975A (ja) | 1994-08-05 | 1996-04-16 | Nippon Bayeragrochem Kk | ５員複素環置換テトラゾリノン誘導体および除草剤 |
| WO1997001551A1 (en) | 1995-06-26 | 1997-01-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole compounds and pharmaceutical compositions |
| US6077850A (en) | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| US6087381A (en) | 1997-05-22 | 2000-07-11 | G. D. Searle & Company | Pyrazole derivatives as p38 kinase inhibitors |
| IL132736A0 (en) | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| CA2291115A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle & Co. | Substituted pyrazoles as p38 kinase inhibitors |
| AU3859999A (en) | 1998-05-14 | 1999-11-29 | G.D. Searle & Co. | 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors |
| EP1131318B1 (en) | 1998-11-20 | 2004-03-24 | G.D. Searle LLC | Process for making 5-substituted pyrazoles using dithietanes |
-
2002
- 2002-09-25 YU YU30504A patent/YU30504A/sh unknown
- 2002-09-25 CA CA002461095A patent/CA2461095A1/en not_active Abandoned
- 2002-09-25 KR KR1020047004396A patent/KR100697482B1/ko not_active Expired - Fee Related
- 2002-09-25 PL PL02369497A patent/PL369497A1/xx not_active Application Discontinuation
- 2002-09-25 MX MXPA04002855A patent/MXPA04002855A/es active IP Right Grant
- 2002-09-25 BR BR0212812-8A patent/BR0212812A/pt not_active IP Right Cessation
- 2002-09-25 JP JP2003530298A patent/JP2005508911A/ja active Pending
- 2002-09-25 EP EP02766355A patent/EP1429773A1/en not_active Withdrawn
- 2002-09-25 AU AU2002330096A patent/AU2002330096B2/en not_active Ceased
- 2002-09-25 US US10/254,445 patent/US6897318B2/en not_active Expired - Fee Related
- 2002-09-25 IL IL16100902A patent/IL161009A0/xx unknown
- 2002-09-25 CN CNB028213173A patent/CN1321644C/zh not_active Expired - Fee Related
- 2002-09-25 WO PCT/US2002/030409 patent/WO2003026663A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL161009A0 (en) | 2004-08-31 |
| US20030144302A1 (en) | 2003-07-31 |
| MXPA04002855A (es) | 2004-07-05 |
| CN1575176A (zh) | 2005-02-02 |
| AU2002330096B2 (en) | 2007-11-08 |
| CN1321644C (zh) | 2007-06-20 |
| US6897318B2 (en) | 2005-05-24 |
| EP1429773A1 (en) | 2004-06-23 |
| JP2005508911A (ja) | 2005-04-07 |
| WO2003026663A1 (en) | 2003-04-03 |
| HK1069535A1 (en) | 2005-05-27 |
| KR100697482B1 (ko) | 2007-03-20 |
| CA2461095A1 (en) | 2003-04-03 |
| PL369497A1 (en) | 2005-04-18 |
| BR0212812A (pt) | 2004-08-03 |
| KR20040081417A (ko) | 2004-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU30504A (sh) | Postupak za dobijanje supstituisanih pirazola | |
| GEP20074135B (en) | Process for the synthesis of (is)-4,5-dimethoxy-1-(methylaminomethyl)- benzocyclobutane and addition salts thereof, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| MY127149A (en) | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | |
| MXPA02012795A (es) | Carvedilol. | |
| JP2004513603A5 (sh) | ||
| WO2002071827A3 (en) | Retinoid x receptor modulators | |
| YU7804A (sh) | Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova | |
| UA96957C2 (ru) | Способ получения галогенидов n-алкилнальтрексона | |
| AU2003303240A8 (en) | Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates | |
| AR039857A1 (es) | Preparaciones de una sulfinilacetamida | |
| PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
| TW200708479A (en) | Process for modifying inorganic oxygen-containing particulate material, product obtained therefrom, and use thereof | |
| ZA200308353B (en) | Compaction process for manufacture of sodium phenytoin dosage form. | |
| AU2002321293A1 (en) | Process for the preparation of methionine | |
| NO20032371L (no) | Makrolidsolvater | |
| MXPA04000847A (es) | Procedimiento para la obtencion de beraprost y sus sales. | |
| HUP0101166A3 (en) | Novel nucleotid sequenzen encoding the dapc gene and process for the production of l-lysine | |
| IL198801A0 (en) | Process for preparing 3,5-di-omicron-acyl-2-fluoro-2-c-methyl-d-ribono-gamma-lactone | |
| TW200508174A (en) | Process for producing cumene | |
| AP2005003259A0 (en) | New process for the industrial synthesis of the methyl diester of 5-amino-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates. | |
| MY136938A (en) | New process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
| GB9929485D0 (en) | Tramadol salts thereof and process for their preparation | |
| DK1399138T3 (da) | Fremgangsmåde til fremstilling af faste formuleringer af natrium-3-hydroxy-3-methylbutyrat | |
| MY135359A (en) | New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof | |
| MXPA03006606A (es) | Proceso para preparacion de analogos de indeno heterociclico. |